--- title: "Bottom-Up Market Sizing, Definition | MedTech Terms" description: "Building market size from procedure volumes × price × penetration. Plain-English Commercialization definition for MedTech teams, with examples and related terms" lang: en json-ld: | { "@context": "https://schema.org", "@graph": [ { "@type": "DefinedTerm", "@id": "https://medtechterms.com/terms/bottom-up-sizing#term", "name": "Bottom-Up Market Sizing", "description": "Bottom-up sizing builds TAM from defensible inputs - incidence/prevalence, procedure volumes, addressable subset, average selling price, and realistic penetration curves - rather than top-down market percentages.", "url": "https://medtechterms.com/terms/bottom-up-sizing", "termCode": "bottom-up-sizing", "inDefinedTermSet": { "@type": "DefinedTermSet", "name": "MedTech Terms", "url": "https://medtechterms.com/terms" } }, { "@type": "Article", "@id": "https://medtechterms.com/terms/bottom-up-sizing#article", "headline": "Bottom-Up Market Sizing", "description": "Building market size from procedure volumes × price × penetration.", "url": "https://medtechterms.com/terms/bottom-up-sizing", "mainEntityOfPage": { "@type": "WebPage", "@id": "https://medtechterms.com/terms/bottom-up-sizing" }, "about": { "@id": "https://medtechterms.com/terms/bottom-up-sizing#term" }, "articleSection": "Commercialization", "inLanguage": "en", "keywords": "Bottom-Up Market Sizing, Commercialization, medical device, MedTech", "author": { "@type": "Person", "name": "Christian Espinosa", "jobTitle": "Founder, Blue Goat Cyber", "url": "https://bluegoatcyber.com" }, "publisher": { "@type": "Organization", "name": "MedTech Terms", "url": "https://medtechterms.com" }, "isPartOf": { "@type": "WebSite", "name": "MedTech Terms", "url": "https://medtechterms.com" }, "datePublished": "2026-05-05", "dateModified": "2026-05-05", "citation": [ { "@type": "CreativeWork", "name": "HCUP", "url": "https://hcup-us.ahrq.gov/", "publisher": { "@type": "Organization", "name": "AHRQ HCUP" } }, { "@type": "CreativeWork", "name": "AdvaMed Code of Ethics", "url": "https://www.advamed.org/our-work/code-of-ethics/", "publisher": { "@type": "Organization", "name": "AdvaMed" } }, { "@type": "CreativeWork", "name": "AHRMM - Healthcare Supply Chain", "url": "https://www.ahrmm.org/", "publisher": { "@type": "Organization", "name": "AHRMM" } } ], "mentions": [ { "@type": "DefinedTerm", "@id": "https://medtechterms.com/terms/tam-sam-som#term", "name": "TAM / SAM / SOM", "url": "https://medtechterms.com/terms/tam-sam-som" } ] }, { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://medtechterms.com/" }, { "@type": "ListItem", "position": 2, "name": "Terms", "item": "https://medtechterms.com/terms" }, { "@type": "ListItem", "position": 3, "name": "Commercialization", "item": "https://medtechterms.com/terms?cat=Commercialization" }, { "@type": "ListItem", "position": 4, "name": "Bottom-Up Market Sizing", "item": "https://medtechterms.com/terms/bottom-up-sizing" } ] }, { "@type": "FAQPage", "@id": "https://medtechterms.com/terms/bottom-up-sizing#faq", "mainEntity": [ { "@type": "Question", "name": "How does bottom-up market sizing relate to regulatory submissions?", "acceptedAnswer": { "@type": "Answer", "text": "While not a direct regulatory deliverable, robust bottom-up market sizing provides critical context for sections of regulatory submissions. It informs the justification for the device's intended use, target patient population, and clinical benefits, aligning with objectives of safety and effectiveness reviews by authorities like the FDA or under the EU MDR." } }, { "@type": "Question", "name": "Can bottom-up market sizing impact risk management?", "acceptedAnswer": { "@type": "Answer", "text": "Yes, a precise understanding of market size, patient demographics, and disease prevalence obtained through bottom-up sizing can enhance risk management activities. It helps in accurately defining the 'intended use' and 'reasonably foreseeable misuse' scenarios as per ISO 14971, contributing to more effective hazard identification and risk control measures." } }, { "@type": "Question", "name": "Is bottom-up market sizing audited by regulatory bodies?", "acceptedAnswer": { "@type": "Answer", "text": "Regulatory bodies do not typically audit market sizing methodologies directly. However, the data and assumptions underpinning the market sizing often relate to clinical evidence, epidemiological data, and intended patient populations that are subject to regulatory scrutiny during device approval processes, particularly concerning claims of clinical benefit and public health impact." } }, { "@type": "Question", "name": "Why is it preferred by ", "acceptedAnswer": { "@type": "Answer", "text": "Bottom-up market sizing is favored by sophisticated MedTech investors because it provides a more granular, evidence-based, and defensible estimate of market potential. It relies on specific, quantifiable inputs like incidence rates and procedure volumes, offering a clearer picture of growth opportunities compared to broader, top-down approaches." } } ] } ] } --- [ MedTech Terms The authoritative reference ](/) Browse Learn [Latest](/latest) About 1. [Home](/) 2. / 3. [Terms](/terms) 4. / 5. [Commercialization](/terms?cat=Commercialization) 6. / 7. Bottom-Up Market Sizing [All terms](/terms) Commercialization [Hospital Buyer & Reimbursement](/ecosystems/hospital-buyer) # Bottom-Up Market Sizing Building market size from procedure volumes × price × penetration. Reviewed by [Christian Espinosa, Founder, Blue Goat Cyber](/authors/christian-espinosa) Last reviewed May 5, 2026 ## Definition Bottom-up sizing builds TAM from defensible inputs - incidence/prevalence, procedure volumes, addressable subset, average selling price, and realistic penetration curves - rather than top-down market percentages. What the regulation says While not directly a regulatory requirement, a well-substantiated bottom-up market sizing contributes to the overall business case and strategic planning reviewed by regulatory bodies like the FDA during pre-market submissions, especially for novel devices. It demonstrates a clear understanding of the target patient population and clinical need, which aligns with the safety and performance objectives of regulations such as the EU [MDR](/terms/mdr-reporting) Annex I, Sections 1 and 8. Detailed market understanding supports risk management activities as outlined in [ISO 14971](/terms/iso-14971), allowing manufacturers to better identify potential harms related to device use in the intended population. ## What this means in practice Preferred by sophisticated MedTech investors. Inputs are sourced from registries (NCDR, STS), claims (HCUP, Medicare 5%/100%), and society reports. ## Examples - A manufacturer of a novel orthopedic implant uses patient registry data and surgical procedure codes (e.g., CPT codes) to estimate the addressable patient population and annual procedure volume. - A company developing a diagnostic test for a rare disease analyzes epidemiological data, insurance claims (e.g., ICD-10 codes), and expert clinician interviews to project the number of eligible patients and average diagnostic test prices. - A startup creating a digital therapeutic for chronic disease management calculates market size based on disease prevalence data from national health surveys, estimated patient engagement rates, and subscription pricing models. Common pitfalls - • Confusing revenue projections with market size, leading to an inflated sense of opportunity. - • Underestimating the burden of evidence required to support incidence and prevalence data, especially when extrapolating from limited sources. - • Failing to account for competitive landscapes and alternative treatments, which can significantly impact market penetration. - • Overlooking the dynamic nature of healthcare, including policy changes, technological advancements, and shifting clinical practices. - • Not adequately documenting the assumptions and data sources used, making the market size difficult to defend or update. ## Frequently asked questions How does bottom-up market sizing relate to regulatory submissions? While not a direct regulatory deliverable, robust bottom-up market sizing provides critical context for sections of regulatory submissions. It informs the justification for the device's [intended use](/terms/intended-use), target patient population, and clinical benefits, aligning with objectives of safety and effectiveness reviews by authorities like the FDA or under the EU [MDR](/terms/mdr-reporting). Can bottom-up market sizing impact risk management? Is bottom-up market sizing audited by regulatory bodies? Why is it preferred by ## Related terms Grouped by theme ### Editor's picks · Hand-selected related concepts [ Commercialization TAM / SAM / SOM Market sizing framework: total, serviceable available, and serviceable obtainable. ](/terms/tam-sam-som) ### More in Commercialization · Same category [ Commercialization AdvaMed Code of Ethics Industry code governing interactions between U.S. medical-device companies and healthcare professionals. ](/terms/advamed-code)[ Commercialization Advisory Board Convening of external experts to advise on strategy or product. ](/terms/advisory-board)[ Commercialization Anti-Kickback Statute(AKS) U.S. criminal statute prohibiting remuneration to induce federal healthcare business. ](/terms/anti-kickback)[ Commercialization Distributor vs Direct Sales Choice between selling through third-party distributors or hiring a direct salesforce. ](/terms/distributor-direct) Cited by Where this term appears across MedTech Terms. Ecosystems (1) - [Hospital Buyer & Reimbursement](/ecosystems/hospital-buyer) ## Primary references 3 sources Link health: 3 verified · last checked 2026-06-20 AHRQ HCUP· 1 AdvaMed· 1 AHRMM· 1 1. [1 HCUP Verified AHRQ HCUP · hcup-us.ahrq.gov ](https://hcup-us.ahrq.gov/) 2. [2 AdvaMed Code of Ethics Verified AdvaMed · advamed.org ](https://www.advamed.org/our-work/code-of-ethics/) 3. [3 AHRMM - Healthcare Supply Chain Verified AHRMM · ahrmm.org ](https://www.ahrmm.org/) Inline markers like \[1\] jump to the matching reference above. Sponsor note ### Selling a connected device into health systems? Hospital procurement increasingly requires MDS2, SBOM, and security questionnaires - we help your team answer them confidently. [Book a 30-minute discovery session](https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session) - No obligation - Expert-led from minute one - NDA available on request MedTech Terms is a community resource sponsored by [Blue Goat Cyber](https://bluegoatcyber.com). Definitions are independent of any vendor. On this term Category Commercialization Sources 3 Updated 5/5/2026 [Compare with another term](/compare?a=bottom-up-sizing) Learn in 60 seconds Card Lesson Quiz Building market size from procedure volumes × price × penetration. - · Preferred by sophisticated MedTech investors. - · Inputs are sourced from registries (NCDR, STS), claims (HCUP, Medicare 5%/100%), and society reports. Remember this Watch out: Confusing revenue projections with market size, leading to an inflated sense of opportunity. Related terms - [TAM / SAM / SOM ](/terms/tam-sam-som) You may also need Auto-suggested from Commercialization and shared keywords. - [Advisory Board ](/terms/advisory-board) - [Distributor vs Direct Sales ](/terms/distributor-direct) - [Group Purchasing Organization(GPO) ](/terms/gpo) - [Managed Service / Reagent Rental ](/terms/managed-service-contract) - [409A Valuation ](/terms/409a-valuation) - [Budget Impact Model(BIM) ](/terms/budget-impact-model) [All Commercialization terms](/terms?cat=Commercialization) MedTech Terms An authoritative, plain-language reference for the regulatory, quality, cybersecurity, and software terms that shape modern medical devices. Browse - [All terms](/terms) - [A–Z index](/a-z) - [Categories](/categories) - [Ecosystems](/ecosystems) - [Learning paths](/paths) - [Compare terms](/compare) - [Quiz](/quiz) Resources - [FDA Medical Devices](https://www.fda.gov/medical-devices) - [EU MDR](https://eur-lex.europa.eu/eli/reg/2017/745/oj) - [IMDRF](https://www.imdrf.org/) - [Methodology](/methodology) - [Changelog](/changelog) - [Editor: Christian Espinosa](/authors/christian-espinosa) - [About this site](/about) © 2026 MedTech Terms. Reference content for educational purposes - not regulatory advice. A community resource sponsored by [Blue Goat Cyber](https://bluegoatcyber.com)